Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syndax Pharmaceuticals

10.25
-0.4200-3.94%
Post-market: 10.250.00000.00%16:31 EDT
Volume:1.31M
Turnover:13.45M
Market Cap:881.99M
PE:-2.66
High:10.58
Open:10.44
Low:10.05
Close:10.67
Loading ...

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires Live
·
16 Jan

Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease

MT Newswires Live
·
16 Jan

Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes

Dow Jones
·
16 Jan

Incyte, Syndax announce FDA approval for Niktimvo vial sizes

TIPRANKS
·
16 Jan

BRIEF-Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvo™ (Axatilimab-Csfr) 9 mg And 22 mg Vial Sizes

Reuters
·
16 Jan

Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February

THOMSON REUTERS
·
16 Jan

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes

THOMSON REUTERS
·
16 Jan

Syndax Pharmaceuticals (SNDX) Gets a Buy from Bank of America Securities

TIPRANKS
·
15 Jan

Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain

Simply Wall St.
·
10 Jan

Barclays Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)

TIPRANKS
·
08 Jan

BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Jan

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire
·
04 Jan

Syndax Pharmaceuticals Restructures Leadership Team

TIPRANKS
·
21 Dec 2024

BRIEF-Syndax Pharmaceuticals Inc - Eliminates Chief Medical Officer Position

Reuters
·
21 Dec 2024

Syndax Pharmaceuticals Inc - Catherine Madigan to Cease as Chief Medical Officer

THOMSON REUTERS
·
21 Dec 2024

Barclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)

TIPRANKS
·
19 Dec 2024

U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart

Reuters
·
17 Dec 2024